---
figid: PMC9700522__NDT-18-2747-g0002
pmcid: PMC9700522
image_filename: NDT-18-2747-g0002.jpg
figure_link: /pmc/articles/PMC9700522/figure/f0002/
number: Figure 2
figure_title: ''
caption: 'Treatment pathway to guide the management of MDD and PRD in adults in the
  SEA region. ^Combination or augmentation treatment regimen in the third line should
  be different from the failed combination or augmentation regimen used in second-line
  treatment. †Esketamine contraindications based on FDA approval: aneurysm; vascular
  disease; known history of atrial cerebral hemorrhage; known history of hypersensitivity
  to esketamine, ketamine or any of the excipients; previous ketamine abuse, bipolar
  disorder. Use with caution in uncontrolled hypertension.'
article_title: A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant
  Depression.
citation: Phern Chern Tor, et al. Neuropsychiatr Dis Treat. 2022;18:2747-2757.
year: '2022'

doi: 10.2147/NDT.S380792
journal_title: Neuropsychiatric Disease and Treatment
journal_nlm_ta: Neuropsychiatr Dis Treat
publisher_name: Dove

keywords:
- depression
- pharmacotherapy
- major depressive disorder
- anti-depressive agents
- depressive disorder – treatment resistant

---
